5-HIAA/5-HT ratio
|
Basic information |
| Metabolite name | 5-HIAA/5-HT ratio |
 | N/A |
 |
N/A |
 |
N/A |
| Synonyms | 5-hydroxyindole-3-acetic acid/5-hydroxytryptamine; |
| No. of studies | 13 |
|
Basic information |
| Metabolite name | 5-HIAA/5-HT ratio |
| N/A |
|
N/A |
|
N/A |
| Synonyms | 5-hydroxyindole-3-acetic acid/5-hydroxytryptamine; |
| No. of studies | 13 |
|
Relationship between 5-HIAA/5-HT ratio and depression (count: 13) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M023 | Type2 | CUMS + middle dose of venlafaxine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M023 | Type2 | CUMS + fluoxetine group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
| Study M079 | Type1 | prolonged LPS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1134 | Type1 | prenatal stress group vs. control group, female offspring | Brainstem | Swiss mouse | Up |
| Study M1134 | Type1 | prenatal stress group vs. control group, female offspring | Hippocampus | Swiss mouse | Up |
| Study M1138 | Type1 | unpredictable subchronic stress group vs. control group | Hippocampus | Swiss mouse | Up |
| Study M1138 | Type2 | unpredictable subchronic stress + imipramine group vs. unpredictable subchronic stress group | Hippocampus | Swiss mouse | Down |
| Study M145 | Type1 | model group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M168 | Type1 | OBX group vs. control group | Cerebrospinal fluid | Wistar rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M542 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M713 | Type1 | CUMS group vs. control group, week 5 | Hippocampus | C57BL/6 mouse | Up |
| Study M713 | Type1 | CUMS group vs. control group, week 3 | Hippocampus | C57BL/6 mouse | Up |
| Study M714 | Type1 | corticosterone group vs. control group, week 3 | Hippocampus | C57BL/6 mouse | Down |
| Study M728 | Type1 | CRS group vs. control group | Prefrontal cortex | C57BL/6 J mouse | Up |
| Study M978 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M978 | Type2 | CUMS + low dose of Rehmanniae Radix group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M978 | Type2 | CUMS + high dose of Rehmanniae Radix group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M978 | Type2 | CUMS + fluoxetine group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M982 | Type1 | adult MDD group vs. adult control group | Plasma | Human | Up |
| Study M982 | Type2 | adult MDD group, post-treatment vs. baseline | Plasma | Human | Down |
| Study M983 | Type2 | adolescent MDD group, post-treatment vs. baseline | Plasma | Human | Down |